Without our health… time to look at Moderna’s stock (NASDAQ: MRNA).In my Outlook 2025, I list 10 stock picks. I also end the picks section with Honorable Mention stocks that I describe as “These stocks faced challenges in 2024, but as we approach 2025, they show promising fundamentals and charts with clear support levels and obvious breakout points.”Moderna (MRNA) is first on that list. Sign up for our FREE newsletter and receive our best trading ideas and research Leave this field empty if you're ...

Key TakeawaysThe S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest rate outlook.Shares of data analytics software firm Palantir lost ground for the second straight session after Morgan Stanley analysts cited valuation concerns.Moderna shares surged as reports of the country's first bird-flu fatality sparked interest in the biotech firm's experimental H5N1 vaccine. Major U.S. equities indexes lost ground as the latest Purchasing Managers' ...

Key TakeawaysModerna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S.The biotech company is developing a vaccine for H5N1.Despite Tuesday's gains, Moderna shares are down more than 55% over the past year. Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1. On Monday, the Centers for Disease Contro ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.77%.The the stock of biotechnology company has fallen by 2.19% in the past month, leading the Medical sector's loss of 6.56% and the S&P 500's loss of 2.82%.Market participants will be closely following the financial results of Moderna in its upcoming release ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and Therapeutics Market by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global mRNA vaccines and therapeutics market size reached US$ 57.7 billion in 2023. Looking forward, the market is expected to reach US$ 72.7 billion by 2032, exhibiting a growth rate (CAGR) of 2.6% during 2023-2032. The development and acceptance of mRNA-based ...

Summary of Moderna, Inc. Conference Call Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Industry**: Biotechnology, specifically focusing on mRNA vaccines and medicines - **Event**: Piper Sandler 36th Annual Healthcare Conference - **Date**: December 5, 2024 Key Points and Arguments Current Position and Market Dynamics - Moderna is recognized as a leading developer of mRNA vaccines and medicines, currently in a strong position with a robust balance sheet and a de-risked mRNA technology platform [2][2] - The company is preparing for several approvals in its late-stage clinical pipeline over the coming years [2][2] COVID-19 Vaccination and Future Products - The company is focused on increasing COVID vaccination rates, particularly among the elderly, who are at higher risk for hospitalization [8][8] - Moderna's next-generation vaccine, mRNA-1283, is expected to have higher efficacy than its previous product, Spikevax, and is aimed at the elderly population [13][14] - The combination vaccine for COVID and flu is anticipated to be crucial in preventing hospitalizations and saving costs [12][12] RSV Vaccine Launch and Market Strategy - Moderna's RSV vaccine, mRESVIA, is entering a market with significant unmet medical needs, particularly for the elderly and pediatric populations [21][22] - The company acknowledges a slower uptake compared to competitors Pfizer and GSK, attributing this to logistical challenges and timing of market entry [31][32] - Future strategies include bundling vaccines to enhance sales and market penetration [34][35] Cytomegalovirus (CMV) Vaccine Development - Moderna is developing a CMV vaccine, which addresses a significant public health issue, particularly in preventing birth defects [36][37] - The CMV vaccine is seen as a potential $2 billion to $5 billion annual market opportunity, with plans to expand its use to pediatric settings [58][58] - The company is preparing educational campaigns targeting OB/GYNs and the general public to raise awareness about CMV and the vaccine [54][56] Safety and Efficacy Considerations - Moderna's RSV vaccine is expected to have a favorable safety profile compared to competitors, as it has not reported cases of Guillain-Barré syndrome in its Phase 3 studies [30][30] - The company emphasizes the importance of data transparency and public health recommendations to encourage vaccination [9][9] Financial Implications - The next-generation COVID vaccine is expected to command a premium price due to its higher efficacy, benefiting both Moderna and retail partners [15][17] - The use of existing manufacturing capacity for the CMV vaccine is projected to yield high gross margins, enhancing the company's financial outlook [60][60] Additional Important Insights - The company is actively working to counter misinformation surrounding vaccines and is committed to transparency in data sharing [9][9] - Moderna's strategy includes leveraging its mRNA technology to create combination vaccines, which could simplify vaccination processes and improve public health outcomes [12][12] - The company is poised to capitalize on the growing demand for vaccines, particularly in the context of respiratory diseases, which are significant health threats in the U.S. [11][11]

Moderna, Inc. (NASDAQ:MRNA) 7th Annual Evercore ISI HealthCONx Conference Call December 4, 2024 1:20 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Conference Call Participants Cory Kasimov - Evercore ISI Cory Kasimov Good afternoon, everyone. I'm Cory Kasimov, one of the senior biotech analysts here at Evercore ISI. It's my pleasure to host our next session with Moderna. And as you can see, we have Lavina Talukdar, the Senior Vice President and Head of Inv ...